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Abstract

Author Manuscript

While current treatment regimens for acute leukemia can dramatically improve patient survival,
there remains room for improvement. Due to its roles in cell differentiation, cell survival, and
apoptotic signaling, modulation of the cyclic AMP (cAMP) pathway has provided a meaningful
target in hematological malignancies. Several studies have demonstrated that gene expression
profiles associated with increased pro-survival cAMP activity or downregulation of various proapoptotic factors associated with the cAMP pathway are apparent in acute leukemia patients.
Previous work to increase leukemia cell intracellular cAMP focused on the use of cAMP analogs,
stimulating cAMP production via transmembrane-associated adenylyl cyclases, or decreasing
cAMP degradation by inhibiting phosphodiesterase activity. However, targeting cyclic nucleotide
efflux by ATP-binding cassette (ABC) transporters represents an unexplored approach for
modulation of intracellular cyclic nucleotide levels. Preliminary studies have shown that inhibition
of cAMP efflux can stimulate leukemia cell differentiation, cell growth arrest, and apoptosis,
indicating that targeting cAMP efflux may show promise for future therapeutic development.
Furthermore, inhibition of cyclic nucleotide transporter activity may also contribute multiple
anticancer benefits by reducing extracellular pro-survival signaling in malignant cells. Hence,
several opportunities for drug repurposing may exist for targeting cyclic nucleotide transporters.

Author Manuscript

#

Correspondence: Ksenia Matlawska-Wasowska, PhD, KMatlawska-Wasowska@salud.unm.edu, 1 University of New Mexico, MSC
10 5090, Albuquerque, NM 87131-0001, Phone: +1 505-272-6177, Fax: +1 505-272-8826, Alexandre Chigaev, PhD,
AChigaev@salud.unm.edu, MSC08 4630 IDTC 2360, 1 University of New Mexico, MSC 09 5025, Albuquerque, NM 87131-0001,
Phone: +1 505-925-7740, Fax: +1 505-272-6995.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered
which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest statement
The authors declare that there are no conflicts of interest.

Perez et al.

Page 2

Author Manuscript

Keywords
Acute myelogenous leukemia (AML); Acute lymphoblastic leukemia (ALL); 3’,5’-cyclic
adenosine monophosphate (cAMP); ATP-binding cassette (ABC) transporters; Efflux, Inhibitors
of cAMP efflux (ICE)

Acute leukemias — Novel therapeutics are urgently required
1.1

Biology and etiology of acute leukemias

Author Manuscript

While not the most prevalent malignancy in the United States, acute leukemia ranks among
the top ten cancers in terms of both morbidity and mortality [1]. These hematological
malignancies involve aberrant proliferation of blood cells with immature phenotypes. Acute
leukemias are typically identified by the presence of > 20% blast cells in the peripheral
blood or bone marrow [2]. Due to inherent characteristics related to a reduced differentiation
state, and the ability to rapidly propagate, acute leukemias may have worse prognoses than
chronic leukemias.
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Acute myelogenous leukemia (AML) is most prominent in elderly adults over 65 years of
age. Annually, 21,450 cases are diagnosed in the United States, and 10,920 cases succumb to
the disease [1]. The five year overall survival for this disease is a disheartening 28.3% for
adults [1] and about 60% for children [3]. T-cell lineage and B-cell precursor acute
lymphoblastic leukemia (T-ALL and B-ALL) primarily affects children, adolescents and
young adults, with about 6,000 new cases diagnosed and 1,500 deaths each year [4, 5]. This
disease is considered > 80% curable, however there is much room for improvement,
specifically for high-risk subtypes such as Ph-like ALL, leukemias harboring
rearrangements of KMT2A gene at 11q23 or BCR-ABL1 translocations, etc. [6–8]
Therefore, there is a strong need for the development of novel approaches to treat these
malignancies and improve patient outcome.
The primary classification of acute leukemia is based on the presence of chromosomal
abnormalities and translocations along with immunophenotyping. For example, 25–30% of
B-ALL have hyperdiploidy [9], while a surprising 40–50% of AML are cytogenetically
normal [2]. An analysis of primary AML samples determined an average of 13 mutated
genes per sample [10]. It has also been reported that > 80% of B-ALL cases contain
deletions within genes related to B cell development [11]. De novo B-ALL genomes also
contain 10–20 gene coding mutations [12].

Author Manuscript

Most commonly, the etiology of acute leukemias is attributed to the combination of
mutations that govern pro-survival signaling and reduce tumor suppressor genes [13]. Many
factors are potentially implicated in leukemogenesis, and most include aberrancies that
increase cell proliferation and induce differential arrest. Due to potential mutations, rapid
growth, and deviant signaling, leukemia cells have the capacity to overcome normal
mechanisms that would typically result in cell death.
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Treatment paradigms in acute leukemias
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Treatment for acute leukemia begins with induction therapy, wherein chemotherapeutic
agents are used to induce remission of the disease. In this approach, the goals are to reduce
the population of blast cells and/or induce them to differentiate. Most commonly, this stage
of treatment involves drugs that are used in many other cancers and diseases, and hence their
mechanisms of action are nonspecific for leukemia. These drugs are aimed at killing all cells
that are proliferating by inducing DNA damage or interfering with cell replication
mechanisms. For some AML and ALL patients, allogeneic stem cell transplants are a
treatment option as well.
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The standard of care for AML is the use of cytosine arabinoside (cytarabine; AraC) with an
anthracycline (e.g., daunorubicin, idarubicin, doxorubicin) for 7–10 days [14]. Over 80% of
patients can achieve a complete response with this treatment, but often relapse will occur
over time [15]. This is followed by consolidation therapy, which is typically high dose AraC
[16]. Refractory or relapsed AML is also treated with high dose AraC, or the FLAG
(fludarabine, AraC, granulocyte colony-stimulating factor (G-CSF)) regimen, but these
result in modest complete remission rates of 32% and 47.5%, respectively [17].
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B-ALL induction therapy involves 4–6 weeks of a glucocorticoid (e.g., dexamethasone or
prednisone), asparaginase, vincristine, and an anthracycline. This is followed by several
months of consolidation and maintenance therapies, which consist of some induction agents,
as well as 6-mercaptopurine or 6-thioguanine, or methotrexate [9]. Like AML, the time
elapsed between remission and relapse was associated with better overall survival. In one
longitudinal study of pediatric B-ALL patients, only 8.8% of participants relapsed within 5
years [18], although other reports have indicated relapse rates of about 15–20% [23].
Nonetheless, a small percentage of B-ALL patients are vulnerable to the development of
extramedullary disease in the central nervous system [19].
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For both AML and B-ALL, remission is often determined by the minimal residual disease in
the bone marrow. Most commonly, this is classified as < 1 leukemic blast in 10,000–100,000
cells [9, 19]. The length of remission varies by patient, although some mutations and
translocations have been associated with longer event free survival. For example, AML cases
with NPM1 mutations are considered to have favorable risk, while those containing an
internal tandem duplication of fms-related tyrosine kinase 3 (FLT3-ITD) have adverse risk
[20]. In B-ALL, the ETV6-RUNX1 fusion protein is associated with better treatment
response and overall good outcome [21]. Rearrangements of the mixed-lineage leukemia
(KMT2A) gene are considered prognostically less favorable [7, 8, 21]. Despite the fact that
these and other cytogenetic factors are characteristically associated with prognosis, many
patient responses to treatment are individual, and even those with similar cytogenetic factors
could have opposite responses to the same therapy.
The treatment paradigms for acute leukemias are not without side effects. Primarily due to
their lack of selectivity for leukemic cells, leukemia chemotherapeutic agents (LCA) can
cause systemic damage to the patient. Most notably, anthracyclines and other
chemotherapeutics exhibit cardiotoxicity. This is probably because, like cancer cells, the
cardiac muscle is highly metabolically active. Survivors of pediatric ALL are at increased
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risk for the long-term development of heart disease [22]. LCA are associated with damage to
the liver and kidneys, as these are the primary organs for drug metabolism. Patients with
ALL are also at risk for osteonecrosis [23, 24]. Furthermore, leukemia treatments have been
related to long-term cognitive impairment, including memory, attention, and executive
function deficits [25, 26]. Hence, the development of drugs that are more selective for
malignant cells could seriously reduce the incidence of adverse side effects suffered by
patients.

cAMP-dependent pathway - A meaningful target in hematological
malignancies
2.1

The cellular roles of cAMP and its regulation

Author Manuscript

In 1958, the first second messenger in cells, 3’,5’-cyclic adenosine monophosphate (cAMP)
[27], was identified. This molecule is critically important for all cells and is central to many
cellular processes that regulate growth, survival, differentiation, and the transcription of a
myriad of genes. cAMP signal transduction can result in activation of pro-survival or death
pathways, depending upon cell type and conditions [28]. The primary downstream effectors
of cAMP are protein kinase A (PKA) and exchange proteins activated by cAMP (EPAC).
While these two effectors can activate multiple transcription factors, the one most commonly
associated with cAMP pathway signaling is the cAMP response element binding protein
(CREB). CREB activity is associated with transcription of many pro-survival genes,
including cyclins A, D1, and D2 [29].

Author Manuscript
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Canonical cAMP synthesis involves activation of any of nine transmembrane-associated
adenylyl cyclases (tmAC), which are stimulated by Gαs-coupled receptors. These activated
receptors are capable of stimulating cAMP synthesis from within endosomes [30].
Activation of Gαi-coupled receptors inhibits tmAC activity, and hence reduces intracellular
cAMP (icAMP). tmACs are envisioned to be responsible for the regulation of cAMP level in
the vicinity of the cell membrane. Additionally, the cAMP signaling is shown to be spatially
segregated throughout the cytosolic compartment, where the second messenger can be
generated by a different enzyme, a non-membrane associated soluble adenylyl cyclase (sAC;
ADCY10). This enzyme is responsible for cAMP production in cytosolic microdomains,
such as the cytoplasm, or within the nucleus or mitochondria [31–33]. Unlike tmACs, sAC is
activated by bicarbonate (HCO3−) or oxidative stress [32, 34–37]. Elevated icAMP triggers
intrinsic apoptosis by PKA signaling. PKA can activate the transcription factor cAMP
response element binding (CREB) protein that triggers up-regulation of the expression of the
pro-apoptotic protein Bim [38]. Additionally, sAC stimulation of PKA can cause
translocation of pro-apoptotic Bax into mitochondria [39, 40]. All these signaling events can
play a role in the activation of the mitochondria-related intrinsic apoptotic pathway.
icAMP concentrations can be modulated by two principal mechanisms. The most commonly
studied cAMP regulators are phosphodiesterases (PDEs). These enzymes hydrolyze cyclic
nucleotides. PDEs 1–4, 7, 8, 10, and 11 are capable of degrading cAMP to 5’-AMP [41].
The second mechanism implies active removal of cAMP from cytosol. The fact that cAMP
can be released outside the cell (ecAMP) was first described in 1963 [42]. Decades later, it
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was determined that icAMP can be actively removed from cytosol via the ATP-binding
cassette (ABC) transporters. The members of the multidrug resistance (MRP) family of
transporters, ABCC4 (MRP4), ABCC5 (MRP5), and ABCC11 (MRP8) are reported to
efflux cAMP [41]. In this review, we focus on the modulation of this process by small
molecules.
Because cAMP activity occurs in discrete locations (microdomains), many cAMP-dependent
regulatory proteins can be complexed to facilitate signal transduction. A-kinase anchoring
proteins (AKAPs) are scaffolding proteins that allow adenylyl cyclases, PKA, and PDEs to
be localized in close proximity to one another [43]. Hence, the compartmentalization of
icAMP into microdomains near the plasma membrane, mitochondria, nucleus, or regulatory
proteins, is a critical determinant of its concentration and activity [44–46] (Figure 1).
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2.2

cAMP targets in acute leukemias
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Considering that icAMP regulation is altered in hematopoietic malignancies, and that
increased icAMP reduces white blood cell survival, the cAMP pathway has long been of
interest as a target for leukemia therapeutics [28, 41, 47–49]. Many cAMP-associated
proteins are dysregulated in acute leukemias. The primary tmAC expressed in lymphoid
cells is the adenylyl cyclase type 7 (ADCY7) [50], and the expression of this protein
inversely correlates with the overall survival of AML patients [51]. The overall PDE activity
was reported to be 10–20-fold higher in certain leukemia and lymphoma cells as compared
to normal blood cells [52]. It should also be noted that glucocorticoids, which are used to
treat ALL, have been shown to downregulate PDE activity [53]. Of note, genomic studies on
primary AML and adult ALL samples have reported overexpression of CREB and/or its
active, phosphorylated form [54–59]. Another study identified downregulation of ICER
(inducible cAMP early repressor), the physiological antagonist of CREB that is associated
with tumor suppression activity [60]. In B-ALL samples, there is an increased incidence of
mutations in transcripts for CREBBP, the binding protein for CREB. These CREBBP
mutations were associated with dominant-negative or deleted activity [61, 62]. To
summarize, acute leukemia cells demonstrate both increased pro-survival cAMP activity
through increased CREB signaling, as well as downregulation of the pro-apoptotic factor
ICER.
2.3

History of cAMP targeting in cancer with a focus on hematological malignancies
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Most previous attempts to modulate cAMP for cancer therapeutics have focused on the use
of cAMP analogs, or by targeting canonical proteins of the pathway through: 1) stimulation
of cAMP production by Gαs-coupled receptors, or 2) inhibition of cAMP degradation by
PDEs. These efforts have had modest success, and are briefly summarized here.
Few cAMP modulating agents targeting cancer have been tested in clinical trials. Despite
demonstrating anticancer effects in vitro and in vivo, phase I clinical trials with the analog 8Cl-cAMP in patients with refractory solid tumors resulted in hypocalcemia and toxicity to
normal tissues [63–65]. A phase II clinical trial evaluated the PDE-inhibitor theophylline for
chronic lymphoblastic leukemia (CLL) patients. Of the 25 CLL patients treated with
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theophylline, only one achieved a complete response, and 18 patients maintained a stable
disease state [66].
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Nonetheless, cAMP pathway modulation has been well investigated as a target in
hematopoietic malignancies in vitro and in vivo. Elevation of icAMP using cAMP analogs
has demonstrated the ability to induce cell cycle arrest (G1 or G2 phase), differentiation,
and/or intrinsic apoptosis in leukemia, lymphoma, myeloma, and normal B cells in vitro,
most often through PKA-mediated mechanisms [38, 67–73]. Similar results have been
reported from studies where cAMP production was stimulated via activation of tmAC [74–
77]. PDE inhibitors have also been employed to increase cAMP signaling in hematopoietic
cells. Meyers, et al. provided evidence that PDE4 inhibition induced cell death in B-CLL
cell lines, but not in normal B and T cells [50]. This selectivity is plausible, since leukemia
and lymphoma cells exhibit elevated PDE expression and activity [49, 52, 78]. Mitton, et al.
used small molecule CREB inhibitors to reduce the expression of pro-survival factors in
AML cells in vitro and in vivo. They showed that this approach induced cell cycle arrest and
apoptosis [59]. Nevertheless, it is important to note that elevated icAMP can also rescue
blood cancer cells from apoptosis, although those studies involved activation of cAMP
signaling after substantial DNA damage had occurred in the treated cells [79–84].
Consequently, there is still substantial evidence to support cAMP pathway targeting in
hematological malignancies.

Targeting cAMP transporters/efflux – an unexplored approach to
modulation of the cyclic nucleotide pathway
3.1

Cyclic nucleotide efflux as a previously overlooked target

Author Manuscript
Author Manuscript

While the intracellular concentrations of cyclic nucleotides are canonically regulated by
degradation by PDE in microdomains [46], efflux mechanisms by ABC transporters are less
explored. This class of proteins consists of 7 families (ABC-A through ABC-G), in which
two molecules of ATP are used to translocate substrates into the extracellular space. As
previously mentioned, cAMP and cGMP are transported by members of the ABCC (MRP)
family, ABCC4 (MRP4), ABCC5 (MRP5), and ABCC11 (MRP8). These transporters are
distributed variably throughout the body, with ABCC4 having the highest expression in the
bladder, kidney, and prostate [85]. The affinity of these transporters varies for cAMP or
cGMP. ABCC5 has a greater affinity for cGMP, whereas ABCC4 is preferential for cAMP
[86]. ABCC4, ABCC5, and ABCC11 regulate xenobiotic metabolism, and they can efflux
antiviral drugs (PMEA, ganciclovir) as well as chemotherapeutic agents (fluorouracil,
mercaptopurine, thioguanine, campothecins, methotrexate). Importantly, these proteins also
serve a role in the transport of natural, endogenous substrates. These include eicosanoids
(e.g., prostaglandins E1 and E2, leukotriene C4), estradiol-17β-glucuronide, folic acid, bile
acids (taurocholate, glycocholate), and some steroids (e.g., DHEAS) [87]. Furthermore, the
cyclic nucleotide transporters also play a major role in relieving oxidative stress, as they
remove glutathione conjugates from the cell [88].
Past work in which cAMP efflux was inhibited by small molecules was performed in
epithelial cell lines, and primarily focused on cAMP concentration changes and the activity
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of the pathway-associated proteins [89, 90]. The efflux capacity of leukemia cells has been
reported as an important factor for predicting patient outcomes [91]. However, the analysis
of cAMP-specific efflux activity has not been extensive. The expression of ABCC4 is
inversely correlated with hematopoietic cell differentiation [92]. Previous studies relied on
the use of indiscriminate ABC transporter inhibitors (e.g., probenecid) or silencing RNA to
block expression of cAMP effluxing proteins [93–95]. These approaches, however, lacked
the efficiency and breadth necessary for resolving the utility of targeting cAMP efflux for
cancer therapeutics.
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Recently, our group initiated studies to further explore the role of cAMP efflux targeting in
acute leukemias [96, 97]. We hypothesized that malignant cells produce and remove the
excess icAMP from mitochondria-containing microdomains to evade intrinsic apoptosis and
to promote cell survival [96]. Consequently, inhibition of cAMP efflux should increase
icAMP and selectively trigger leukemia cell death. We proposed that small molecule cAMP
efflux inhibition, if achieved using existing drugs through a repurposing strategy, has the
potential to expedite the translation of cAMP efflux-targeting therapeutics [96]. Because
elevated cAMP efflux activity could be a specific adaptation of malignant cells that is not
apparent in normal cells, drugs developed using this approach have the potential to
selectively target leukemia or other tumor cells.
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To monitor cAMP efflux from living cells and primary patient samples, we designed and
patented a novel assay that rely on cellular retention of a fluorescent cAMP analog (FcAMP) [98]. This assay was later adapted for use in a high throughput flow cytometry
platform [97]. After screening two chemical libraries consisting of off-patent FDA-approved
drugs and biologically active compounds, we identified and validated six compounds termed
“inhibitors of cAMP efflux” (ICE) [96, 97].
Using the F-cAMP-based approach, our group confirmed that cAMP efflux was
undetectable in normal peripheral blood mononuclear cells (PBMCs) but was active in
leukemia cell lines [96]. Several interpretations for this phenomenon can be considered. As
mentioned before, the cAMP efflux could be a malignancy-specific adaptation directly
related to the evasion of apoptosis in cancer. It can be also related to a metabolic specificity
of leukemic cells (Warburg effect). cAMP is a well known regulator of cellular respiration,
metabolism and an accumulation of cAMP in cancer cells can trigger metabolic
reprogramming, mitochondrial biogenesis and anti-Warburg effect [99]. The fact that normal
hematopoietic progenitors exhibit an increased expression of ABC transporters capable of
cAMP efflux [92], a phenotype that is shared by blasts associated with acute leukemias
[100], can indirectly support this idea.
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Previously, Copsel et al., demonstrated that blocking cAMP efflux in an AML-relevant
model system not only increased icAMP accumulation, but also triggered a series of
downstream signaling events relevant to the pathway activation [93, 94]. We also validated
the ability of newly identified ICE compounds to increase cAMP pathway activity by
demonstrating its ability to modulate cellular downstream signaling. This included CREB
(pS133) / ATF-1 (pS63) phosphorylation and CD49d/CD29 (VLA-4) integrin deactivation
[96]. Active VLA-4 integrin is responsible for homing and retention of hematopoietic blasts
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and other cells in the bone marrow. Deactivation of this adhesion molecule by cyclic
nucleotide-dependent signaling mechanism is crucial for mobilization of white blood cells
into the peripheral blood [101, 102], and activation of VLA-4 integrin is known to be
impaired in a subset of CLL patients [103]. Our experiments further demonstrated that the
ability of ICE to reduce cell viability was partially dependent on the activity of sAC, a
source for cytosolic, mitochondrial, and nuclear cAMP production [36, 104]. Furthermore,
ICE reduced the viability of leukemia cell lines and ex vivo primary patient samples at much
lower concentrations than required for PBMCs, indicating that cAMP efflux inhibition could
be a feasible target for malignant cells. Because several identified ICE are FDA approved
drugs, these studies provide a potential path for drug repurposing against leukemias [96].
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We also compared ABCC4 expression in several leukemic cell lines and determined that
there was no apparent relationship between antibody binding and the F-cAMP efflux ability
[96]. The simplest explanation here is the possibility that transporter activity is regulated by
protein modification, such as phosphorylation, for example. The best-studied member of
ABCC subfamily, ABCC7, was shown to be phosphorylated by PKA and this directly
affects its activity [105]. Another possibility is that ICE may act by some alternative
mechanism(s) unrelated to transporter inhibition per se. Finally, the work by Guo, et al.
previously showed that, of the known cAMP efflux transporters, only the expression of
ABCC11 was prognostically relevant in leukemia [106]. Other studies have indicated the
possibility for the ABCC1 and ABCG2 transporters to efflux cyclic nucleotides [95, 107]. It
is therefore plausible that acute leukemia cells may reduce intracellular cAMP using
ABCC5, ABCC11, or other MRP transporters.
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It should be emphasized that the cross-competition between transporter substrates can
theoretically perturb transport activity resulting in the inhibition of one with another. Hence,
it is possible that some molecules identified as inhibitors of a given transporter may instead
reduce the efflux of other substrates, without actually blocking the activity of that
transporter. Extensive mechanistic studies are needed to validate the mechanism of action of
efflux inhibitors on transporters. It should be noted that all substrates of a transporter have
the potential to inhibit the transport other substrates of the same transporter. Therefore,
molecules that affect similar pathways could initially be identified as efflux inhibitors, but
may in fact potentially have mechanism(s) of action that are unrelated to antagonism of
transport proteins.
3.2

ICE and distinct intracellular cAMP compartments. Design of cAMP signalosomes
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cAMP signaling is highly compartmentalized and responses to cAMP are spatially and
temporary restricted. Thus, it is necessary to understand the effects of ICE on major cellular
functions, such as cell proliferation, differentiation and cell death. This should be done in the
context of cAMP signalosomes, large multi-protein complexes that consist of key players of
the cAMP signaling pathway. A representative cAMP signalosome includes several
components. Scaffold AKAP proteins provide binding sites for all other signalosome
components, and organize as well as target the complex to a specific cellular location. For
example, AKAPs that target signalosomes to the plasma membrane are AKAP7, the smallmembrane AKAP (smAKAP, C2orf88) [108]. AKAP1 (D-AKAP1, S-AKAP84, AKAP121)
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target signalosomes to the outer mitochondrial membrane or the endoplasmic reticulum
[109, 110] and AKAP6 (mAKAP), one of the proteins that targets signalosomes to the
nuclear membrane [111]. Other components of the signalosome include cAMP-dependent
protein kinase PKA, and the PDE responsible for the degradation of cAMP and other
proteins. This specific signalosome organization that places proteins in close proximity to
one another is envisioned to provide tight regulation of cAMP/PKA signaling in specific
cellular compartment. In resting cells, PDEs maintain a low concentration of localized
cAMP that is insufficient to activate PKA. Upon activation of AC, increased cAMP
production triggers PKA activity. The subsequent phosphorylation of PDE by PKA
stimulates cAMP hydrolysis and returns cAMP levels to the resting state. Disruption of the
interaction between PKA and AKAP blocks PKA induced PDE activation [112]. This
suggests that spatial organization of the signalosome, where proteins are anchored in
proximity to one another is essential for proper functioning of the signaling mechanism.
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To decipher how ICE may affect distinct cellular compartments, here we focus on known
functions of the PKA/cAMP pathways in mitochondrial, nuclear, and plasma membrane as
well as cytosolic signalosomes.
3.2.1

Mitochondrial cAMP-PKA signaling
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Several excellent reviews that describe cAMP signaling in mitochondrial compartment were
recently published [113, 114]. Here we will briefly focus on main functions of cAMPdependent processes that are important for understanding the potential effects of ICE on
mitochondria. The outer mitochondrial membrane is permeable for small molecules [115],
and therefore, cAMP produced by tmACs and sAC in the cytosol can reach the
intermembrane mitochondrial space. However, the inner mitochondrial membrane is
impermeable to cAMP. As mentioned above sAC could be a source of cAMP in the
mitochondrial matrix [31, 32].
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In mitochondria, oxidative phosphorylation (OXPHOS) [32], protein import into
mitochondria [116–118], mitophagy, mitochondrial fission and fusion [113], metabolic
reprogramming and the anti-Warburg effect [99], as well as the intrinsic apoptotic pathway
[38], can all be modulated by the cAMP-PKA-related signaling pathway. However, it seems
that the majority of these processes can be affected by cAMP diffusing to the outer
mitochondrial membrane. Only OXPHOS and metabolic reprogramming/anti-Warburg effect
require cAMP level changes in the mitochondrial matrix. As ABCC transporters that
represent a potential target for ICE are expressed in the plasma membrane, it is expected that
blocking cAMP efflux can have direct effects on protein import, mitophagy and
mitochondria-induced apoptosis. Our recent data suggest that in leukemic cells ICE can
trigger four apoptotic endpoints including mitochondrial membrane depolarization and
activation of effector caspases 3 and 7 [96]. Thus, it is plausible that cAMP produced by
tmAC can reach the outer mitochondrial membrane and trigger AML cells apoptosis.
We also found an unexpected connection to potential dysregulation of protein import in adult
AML patient samples. Our analysis of several related gene expression clusters associated
with poor outcome, worse overall survival and highest rates of resistant disease revealed
enrichment for genes related to transport across membranes (transporters, carriers and
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channels). One of the identified genes was TOMM7, the mitochondrial import receptor
subunit translocase of outer membrane (TOM) homolog [119]. This protein regulates
assembly and stability of the main translocase complex [120]. The up-regulation of TOM7
in AML cells may be related to aberrant protein import in cancer. It is envisioned that
defects in protein translocation into mitochondria can be devastating for organelle function,
since the TOM complex provides an entry point for 99% of all precursor proteins in
mitochondria [121, 122]. While cAMP-PKA signaling can diminish import of proteins
through TOM and triggers the switch from OXPHOS to glycolysis [114], it is not known
whether it can be directly related to the defects of the TOM system in leukemia. Does
cytosolic sAC, activated by HCO3−, low pH or oxidative stress [32, 34–37], produce cAMP
that triggers mitochondrial protein import dysfunction in cancer? How these changes are
related to the Warburg effect? All these questions should be examined in the future.
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3.2.1

Plasma membrane and cytosolic compartments
The plasma membrane and cytosolic compartments are the most studied among all cAMPPKA-related sites. Before the concept of cAMP signaling compartmentalization was
introduced, it was assumed that the main site of cAMP-PKA signaling was the plasma
membrane and cytosol. Numerous reviews of the field exist. Thus, here we discuss a few
novel and previously unrecognized players.
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As mentioned above, tmAC activity is controlled by two types of GPCRs, Gαs-coupled
(stimulating cAMP production) and Gαi-coupled (inhibiting) receptors, the majority of
which are localized to the plasma membrane. cAMP that is produced by tmACs diffuses in
cytosol. CXCR4 (Gαi-coupled) and CXCR7 (a non-classical GPCR that can form
heterodimers with CXCR4, acting as scavengers for the CXCR4 ligand CXCL12) are both
relevant to leukemia and other cancers [123]. The idea that elevated signaling thorough Gαscoupled H2-histamine receptor can be beneficial for treatment of AML [124], supports the
notion that cAMP elevation in the cytosolic compartment using ICE is also beneficial [96].
Unfortunately, in some myeloid cells despite the elevation of the cAMP level that resulted
from H2-histamine receptor stimulation, cell differentiation failed to occur. To explain this
discrepancy, the authors suggested that cAMP efflux through MRP transporters could be
modulating the cAMP level [124]. This notion evokes the suggestion that combining ICE
with H2-histamine agonists could be an option to overcome this problem. Another report
that shows an improvement in immune checkpoint therapy by activating the Gαs-coupled G
protein-coupled estrogen receptor (GPER) indirectly supports this idea [125].
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Hematological malignancies are characterized by the presence of a substantial number of
cells exhibiting immature phenotypes. In acute leukemias up to one fifth or more of total
cells can show blast morphology in the peripheral blood [2]. This reinforces the idea that
leukemic cells possess a defect in their adhesion molecules, resulting in a premature release
from the bone marrow niche into the peripheral blood. VLA-4 integrin is critical for homing
and retention of hematopoietic blasts in the bone marrow niche, and it can be inactivated by
a cyclic nucleotide-dependent signaling mechanism [101, 102]. The finding that the
cytoplasmic domain of the VLA-4 subunit (alpha4, CD49d) serves as a type I PKA-specific
AKAP puts VLA-4 integrins right at the heart of the plasma membrane cAMP signalosome.

Semin Cancer Biol. Author manuscript; available in PMC 2022 January 01.

Perez et al.

Page 11

Author Manuscript

Sequestering type I PKA away from VLA-4 dramatically reduced VLA-4 subunit
phosphorylation and inhibited VLA-4 dependent migration toward CXCL12 [126].
The role of the VLA-4-PKA protein complex in leukemia pathogenesis is not known.
Similarly to VLA-4, the cAMP efflux transporters (a likely target for ICE compounds) are
localized in the plasma membrane. Thus, they can also play the roles in the regulation of
plasma membrane cAMP signalosome. The fact that the effect of ICE on VLA-4 functional
activity can be detected within seconds after compounds addition suggests a very close
association between these signaling complexes (see Figure 4 in [96]). It is also possible that
blocking cAMP efflux at the plasma membrane results in cAMP accumulation and
subsequent diffusion toward the mitochondrial outer membrane, where it can affect PKA
activity, modulate protein import and trigger apoptosis.
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3.2.3

Nuclear compartment
CREB and activating transcription factor-1 (ATF-1) are the classical cAMP effectors that
activate target genes through cAMP response elements (CRE). This pathway is directly
implicated in cAMP-induced apoptosis in leukemia [38]. Because the mitochondrial
proteome largely originates from nuclear DNA, CREB together with downstream
transcription factors, peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1α)
and nuclear respiratory factors (NRF), activates transcription of numerous mitochondrial
genes and promotes biogenesis of mitochondria [127, 128].
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There are multiple indications of aberrant CREB function in leukemia. CREB is shown to be
overexpressed in primary samples obtained from AML and ALL patients [29, 129]. CREB
expression was associated with increased risk of relapse and lower rate of the event-free
survival [130]. CREB inactivation inhibited AML cell proliferation and triggered apoptosis,
while had no significant effect on normal hematopoietic stem cells [54], prompting the
development of small molecule modulators of CREB [131]. A recent report shows that a
small molecule inhibitor of CREB, XX-650–23 blocked interaction between CREB and its
co-activator CBP, and was capable of triggering apoptosis, and cell-cycle arrest in AML
cells. Moreover, it increased mice survival in human AML xenograft models, suggesting that
targeting CBP–CREB interaction may represent a novel approach for AML therapy [59].
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In our experiments, ICE were capable of increasing CREB (pS133) phosphorylation [96],
which is known to induce the formation of a complex between CREB and CBP [132]. These
findings seem to tilt the signaling balance towards CREB pathway activation, which in AML
cells is interpreted as pro-survival signal. ICE were capable of inducing the loss of
mitochondrial membrane potential within 2 h after treatment [96]. We proposed that ICEinduced the elevation of cAMP targeted primarily the mitochondrial cAMP-PKA
compartment resulting in initiation of the intrinsic apoptotic pathway [38]. CREB (pS133)
phosphorylation was simply an indicator of activation in another cAMP-dependent pathway.
To summarize, ABCC4, ABCC5 and ABCC11 are localized in the plasma membrane.
Therefore, targeting cAMP efflux by ICE is expected to affect intracellular compartments
that are spatially adjacent to this compartment. Also, it is anticipated that the cAMP
compartment that provides easy access to cytosolically produced cAMP would be primarily
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affected by diminished cAMP efflux. Thus, ICE are expected to target processes that can be
modulated by plasma membrane and cytosol, outer mitochondrial membrane and nuclear
signalosomes.
3.3 Cyclic nucleotide transporter inhibition potentially provides multiple anticancer
benefits
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Because the inhibition of cyclic nucleotide efflux obviously results in increased intracellular
concentrations of transporter substrates, it can be expected that signaling processes will be
affected accordingly. As previously mentioned, elevated icAMP signaling can result in the
activation of the intrinsic apoptotic pathway. Conversely, extracellular cAMP (ecAMP) can
result in autocrine and paracrine signaling. ecAMP has been shown to reduce immune cell
activation [133], and thus cAMP efflux may provide another survival advantage for
malignant cells by allowing them to avoid clearance by a normal immune response.
Furthermore, Bhang, et al. have demonstrated that extracellular PKA, a downstream effector
of ecAMP, was significantly elevated in the sera of dogs with cancer in comparison to
healthy dogs or those with other diseases [134]. The authors do not speculate as to the
purpose of extracellular PKA, although others have indicated that it may aid in the activation
of prostaglandin H synthase [135], a factor related to cancer angiogenesis [136].
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Another interesting aspect of ecAMP signaling relates to the existence of an ecAMP/
adenosine pathway. Here, extracellular cAMP, which presumably has exited the cell through
an efflux transporter (or leaked passively), is converted into adenosine by the activity of the
ectonucleoside triphosphate diphosphohydrolase-1 (ENTPDase1) and ecto-5’-nucleotidase
(NT5E), CD39 and CD73, respectively [137]. Some researchers have suggested that this
pathway exists because free adenosine has a very short half-life, whereas ecAMP is stable in
plasma, allowing it to participate in regulated signaling processes [138].
The adenosine produced by the hydrolysis of ecAMP can play many roles. The adenosine
generated by CD73 activity is associated with increased tumor growth and suppression of
normal immune responses [139–142]. Leukocytes express the adenosine receptor A2A
(A2AR), a Gαs-coupled receptor [143]. The activation of A2AR can induce several
downstream signaling cascades. Importantly, A2AR can stimulate a positive feedback
mechanism where cAMP production, cAMP efflux through ABCC4, and ecAMP hydrolysis
can promote more A2A stimulation [144, 145]. As such, inhibition of A2A receptors is
capable of inhibiting the growth and metastasis of tumor cells [146–150].
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It is conceivable that leukemia cells exploit this ecAMP/adenosine pathway activity, though
the linkage is not straightforward. Expression of ectonucleotidases may be triggered by
hypoxia [151], which is a key characteristic of the bone marrow microenvironment. An
analysis of whole blood from patients indicated that CD39 was expressed on > 90% of both
normal and malignant B-cells, and 8% of normal T cells. Elevated CD39 activity was
associated with earlier stages of CLL, whereas decreased CD39 was associated with worse
disease [152]. Inhibition of CD39 activity has been proposed as a potential anticancer target
[153–155]. Another study has shown that 32% of CLL patients expressed CD73, and that
this enzyme was associated with reduced response to therapy [156]. Similarly, CD73
expression on ALL cells was significantly related to expression of CD10, a protein
Semin Cancer Biol. Author manuscript; available in PMC 2022 January 01.

Perez et al.

Page 13

Author Manuscript

associated with progenitor phenotypes [157]. Moreover, gene expression analysis of a drug
resistant T-ALL cell line identified increased CD73 expression and resistance to receptormediated apoptosis, although the authors hypothesized that a direct interaction between
CD73 and the cell death receptor, rather than CD73 enzymatic activity, may have been the
mechanism of action [158]. Furthermore, CD73 appeared to have no prognostic value in
predicting pediatric ALL response to therapy [159].

Author Manuscript

Another substrate of cyclic nucleotide transporters merits mention here, prostaglandin E2
(PGE2). PGE2 itself is associated with pro-survival signaling, through its binding to the
Gαs-coupled receptors EP2 (PTGER2) and EP4 (PTGER4). Here, the downstream signaling
is analogous to A2AR. Acute leukemia blast cells express EP2 [160], hypothetically in
response to PGE2 secreted by bone marrow mesenchymal cells [161]. In principle, PGE2
could inhibit bone formation via increased icAMP signaling through EPAC, allowing for
remodeling of the bone marrow microenvironment [162]. We propose that PGE2-mediated
signaling may occur in an autocrine manner, by the PGE2 effluxed by cyclic nucleotide
transporters.

Conclusions
This review has highlighted the need for new treatment regimens for acute leukemias. We
have described the vital roles that cAMP signaling plays in the regulation of cell
proliferation, survival, and apoptosis. We provided justification for targeting the cAMP
pathway, since pathway-associated proteins are dysregulated in these malignancies. We also
introduced the concept that the reduction of cyclic nucleotide efflux activity could
potentially provide multiple anticancer benefits.
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Because chemotherapy resistance can occur by cAMP efflux transporters [106, 163], there is
a possibility of using cAMP in combination with current therapeutics to produce synergistic
effects against leukemias. Synergism produced by these drug combinations would be
beneficial for decreasing leukemia cell burden, and potentially to reduce the likelihood of
resistance and/or relapse. Because several FDA approved drugs showed ICE activity, an
opportunity for an accelerated introduction of novel therapeutics thorough a drug
repurposing mechanism represents an exciting possibility [96].
In sum, this review could provide support for a new class of antileukemia drugs, cAMP
efflux inhibiting compounds, to be tested in clinical trials. This new approach would be
significant because it could substantiate inhibition of efflux as a paradigm shift in cAMP
pathway targeting for cancer therapeutics.
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Figure 1. Basic schematic of cAMP compartmentalization and effectors.

cAMP (green) is produced by transmembrane (tmAC) or soluble (sAC) adenylyl cyclases.
Intracellular cAMP (icAMP) is downregulated by PDEs or efflux by ABC transporters to the
extracellular space (ecAMP). icAMP can activate the downstream effectors EPAC and PKA.
ecAMP can activate ePKA, or it can be hydrolyzed by the enzymes CD39 and CD73 into
adenosine, which can then stimulate its receptors. EPAC, exchange proteins activated by
cAMP. Gαs-GPCR, stimulatory G-protein coupled receptor. PKA, protein kinase A. ROS,
reactive oxygen species.
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